Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2020 07:57 ET | Source: Aptinyx Inc.

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
December 09, 2019 16:05 ET | Source: Aptinyx Inc.

Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting

EVANSTON, Ill., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...